Tesofensine / Dihexa is a fixed-combination research formulation supplied as solid-format tablets for controlled laboratory workflows. Each tablet contains tesofensine (250 mcg) and dihexa (as specified in batch documentation), with 60 tablets per container. Batch-specific Certificates of Analysis document active-component identities, per-tablet content verification, physical characteristics, and relevant excipient information to support reproducibility and documentation control.

This formulation is evaluated exclusively in controlled in-vitro research systems investigating monoaminergic signaling dynamics, neurotrophic pathway modulation, and synaptic signaling models under defined laboratory assay conditions.

This multi-analyte formulation is characterized for use in analytical and cell-based models examining interactions between neurotransmitter reuptake modulation and hepatocyte growth factor–related signaling pathways. Applications include studies of synaptic signaling behavior, receptor- and transporter-associated responses, neuroplasticity-related pathway activation, and pathway cross-talk between small-molecule and peptide-mimetic components.

Each production lot is qualified at 99%+ purity using high-performance liquid chromatography, with compound identities confirmed by mass spectrometry. Independent third-party laboratories corroborate in-house analytical results. Manufacturing documentation, including Certificates of Analysis, raw-material sourcing, and complete batch records, is maintained to support traceability, institutional procurement review, and audit readiness.

• For in-vitro research only
• Not for human or animal consumption
• Not for diagnostic or therapeutic use